Latest Supply Chain News

Viridis Mining and Minerals has been selected for up to US$903 million in Brazilian government funding to advance its Colossus Rare Earth Project, while delivering Brazil’s first locally sourced rare earth oxides and posting robust Pre-Feasibility Study results.

Elixinol Wellness reported a 10.8% revenue increase in Q2 2025, supported by improved cash receipts and a focused cost containment program. The company secured new funding and launched a menopause-targeted product, positioning itself for margin growth and profitability in H2.

International Graphite Limited (ASX, IG6) has signed a cooperation agreement to develop a 3,000 t/y expandable graphite facility in Germany, advancing its global footprint alongside progress at its Collie micronising plant and Springdale project, supported by potential US Department of Defense funding.

Cobalt Blue Holdings has completed a promising scoping study for its Halls Creek copper-zinc-silver project and secured a key cobalt feedstock contract with Glencore, setting the stage for a final investment decision on its Kwinana Cobalt Refinery by year-end.

Provaris Energy has marked significant milestones in Q2 2025 with a key MOU with global shipping leader 'K' LINE and a joint venture formation with Yinson to commercialise proprietary hydrogen and carbon dioxide transport technologies.

Macro Metals Limited has secured two non-binding letters of intent from licensed Singaporean importers for trial shipments of up to 600,000 cubic meters of sand from its Port Hedland deposit, marking a significant step in its export ambitions.

Eclipse Metals Ltd reports a transformative quarter with a massive upgrade to its Greenland rare earth resource and strategic advances in its uranium portfolio, backed by a $2 million capital raise.

TerraCom reported steady coal sales for the June quarter despite softer thermal coal prices and weather disruptions, opting to withhold dividends while advancing key projects.

Tissue Repair Limited reports steady progress in its Phase 3 clinical trials for TR987® despite patient recruitment hurdles, while TR Pro+® sales surge and new distribution deals pave the way for international growth.

Clarity Pharmaceuticals has bolstered its cash reserves to approximately $288 million following a $203 million institutional placement, while reporting significant clinical progress across multiple copper-based radiopharmaceutical trials targeting prostate cancer and neuroendocrine tumours.

Cadoux Limited has made significant progress in developing its high purity alumina and rare earths projects, advancing engineering design, customer engagement, and funding strategies during the June 2025 quarter.

Carbonxt Group Limited advances its Kentucky activated carbon facility with increased ownership and imminent kiln commissioning, while securing $1 million in convertible notes to support growth. The company reports steady revenue and strong market positioning amid tightening US EPA PFAS regulations.